Estrella Immunopharma, Inc. (ESLA) is a clinical-stage biopharmaceutical entity with no revenue, no inventory, and no tangible fixed assets of consequence. The 10-K/A filed April 30, 2026 is an amendment solely adding Part III (governance, compensation, ownership) and updated Section 302 certifications; it contains no revised financial statements. All balance-sheet data therefore derives from the Original Form 10-K for the fiscal year ended December 31, 2025. Under a liquidation lens, recovery to equity is deeply negative. Total assets are $3.18M against total liabilities of $13.54M, yielding a book equity deficit of -$10.37M. MFFAIS reports CLV/LLV/OLV of approximately -$12.2M, consistent with haircut analysis: cash of $1.38M recovers at par; prepaid and other current assets of $0.29M recover at ~90%, contributing roughly $0.26M; the $1.5M non-current deposit with Eureka (prepaid for patient treatment expenses under the STARLIGHT-1 SOW) is a related-party receivable with uncertain collectibility in a wind-down and should be haircut to near zero in a distressed scenario. Intangible value of the ARTEMIS T-cell technology license is zero under liquidation convention. On the liability side, all obligations stand at face value: current liabilities of $13.54M are dominated by accrued liabilities - related party of approximately $12.4M representing milestone obligations owed to Eureka Therapeutics under the $33M SOW for the Phase I/II EB103 clinical trial. This single related-party accrual, which was approximately $2.8M as of December 31, 2024 (per prior Q3 2025 filing disclosures showing $12.9M as of September 30, 2025), expanded materially through fiscal 2025 as additional patient-dosing milestones were completed. There is also a derivative liability of $0.36M (True-Up Shares from 2025 PIPE transactions, fair-valued via Monte Carlo). No debt, no lease liabilities, no pension. The filing discusses the $33M total SOW commitment and milestone-driven accrual structure in MD&A but does not separately XBRL-tag the total remaining unfunded commitment beyond what is accrued; this off-balance-sheet exposure (approximately $29.5M unaccrued of $33M total, net of amounts already paid and accrued) is a further contingent liability not captured in the face-value liability stack. Going-concern language is implicit given accumulated deficit of -$36.99M and cash of $1.38M against an operating burn of approximately $1.8M in operating cash outflows for fiscal 2025, though the majority of the operating loss ($10.25M R&D, driven by the Eureka SOW accrual) is non-cash milestone accrual rather than cash-settled. Eureka Therapeutics holds 59.3% of common stock, making this a controlled entity with significant related-party concentration on both the asset and liability sides.
▼ Community Notes